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Abstract
Objective: The objective of this selective EBM review is to determine where or not “Are Cox-2
inhibitors such as celecoxib and parecoxib effective in reducing post-tonsillectomy pain?”
Study Design: Review of three double blind randomized controlled trials (RTC).
Data Sources: All studies were published in peer-reviewed journals found via the use of
PubMed.
Outcomes Measured: Patients were divided into two groups: those who received the Cox-2
inhibitor and those who received the placebo, in order to measure postoperative pain using
patient or parent reported journals or diaries, questionnaires, and various pain scales (CHEOPS,
and WP24HR with VAS).
Results: Two out of three studies show a modest, but clinically significant decrease in pain post
tonsillectomy with or without adenoidectomy. However, one study did not show a change in
pain scores between the Cox-2 group and the placebo. Using parecoxib as the drug, Li X
showed Group P had significantly lower CHEOPS scores than Group S (7 [5-8] vs. 9 [8-11]
respectively. P=0.001). Murto et al showed the celecoxib group resulted in an 11% reduction in
WP24HR score averaged over POD 0-2 (95% CI: 0.3-14. P=0.04) and additionally a 14%
increase in WP24HR pain scores on POD 3 after the cessation of the intervention. Van Daele et
al did not show a statistically significant decrease in pain between the two groups even though
the scores for the intervention group were generally lower than the placebo.
Conclusions: Two out of the three randomized controlled trials studied reported statistically
significant decrease in pain post tonsillectomy with or without adenoidectomy in the intervention
group versus the placebo. Van Daele et al concluded that there was no statistical significant
decease in pain between the two groups, however, this study used patients eighteen and older,
which varied from the other studies. With this information it can be concluded that in children
aged two to eighteen, Cox-2 inhibitors do show a statistically significant decrease in pain post
tonsillectomy. Further studies are warranted in order to determine significance in an older
patient population.
Key Words: Cox-2 inhibitors, pain, and tonsillectomy
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Introduction
Tonsils are two clusters of soft tissue located on both sides of the posterior throat.
Tonsillectomies are a surgical procedure used to remove the tonsils for various reasons including
recurrent tonsillitis, recurrent pharyngitis, and obstructive sleep apnea1. Over the years much has
changed in terms of procedure, guidelines, and recovery. In 2011, American Academy of
Otolaryngology released a clinical practice guideline to help physicians and parents better
understand the indications of surgery and to better optimize the before and after care of patients
undergoing a tonsillectomy2. Every patient undergoing a tonsillectomy experiences postoperative pain that is monitored and treated appropriately. Cyclooxygenase-2 (Cox-2) inhibitors
are a type of NSAID that selectively blocks only the Cox-2 enzyme, which is usually responsible
for the pain and swelling associated with inflammation3. These drugs are different than other
NSAIDs, which block both Cox-1 and Cox-2 enzymes. In previous studies, 15 out of 20 have
shown that when used preoperatively, COX-2 inhibitors, specifically celecoxib, are better with
postoperative pain as compared to a placebo4. This paper evaluates three double blind
randomized controlled trials that compare the efficacy of celecoxib and parecoxib (Cox-2
inhibitors) as medication to reduce post-operative pain after a tonsillectomy.
This topic is relevant to the PA scope of practice because it is important for a PA to
determine the indications for surgery, and how to care for patents pre- and post -operatively. In
the United States, tonsillectomies are the 3rd most common procedure performed on children or
about 530,000 a year, 186,000 being performed on patients 15 years or older4. Patients aged 15
or younger make up 20% of all otolaryngology visits a year, patients aged 15-24 makes up 7%
and patients aged 25-44 makes up 21%5.
In the United States the cost of a tonsillectomy varies based on your location and type of
insurance. There are a variety of different elements that contribute to the overall cost that
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patients often do not factor in, including but not limited to, the pre-operative appointment, the
post-operative appointment, if necessary antibiotics and additional any visits to deal with
complications. Overall, the cost for uncomplicated tonsillectomy was around $3,832, while the
cost for tonsillectomies with complications was $6,388 for hemorrhage, $5,753 for dehydration,
and $4,708 for pain6.
There are a multitude of complications associated with tonsillectomies each with their
own treatment and risks. An important obstacle facing healthcare professionals is finding the
best post-operative medical management to control pain with minimal side effects. Independent
of the technique used, substantial pain, decreased diet and reduced activity are seen. Regardless
of the age of the patient, adequate pain control is needed in order to ensure the patient stays
hydrated and makes a full recovery as soon as possible5. Cox-2 inhibitors are not commonly
used as a post-operative medication to treat pain. Instead, patients use a combination of
acetaminophen and ibuprofen and on rare occasions morphine to reduce pain6. As stated
previously, Cox-2 inhibitors work solely on the Cox-2 enzyme, which is usually responsible for
the inflamed tissue. Cox-2 inhibitors have been indicated to treat acute pain as well as pain
secondary to arthritis. Consequently, they could be beneficial after a surgery where there is a
significant amount of inflammation causing prolonged pain for the patient.
Objective
The objective of this selective EBM review is to determine whether or not “Are Cox-2 inhibitors
such as celecoxib and parecoxib effective in reducing post-tonsillectomy pain?”
Methods
The studies used in this systematic review included three double blind, randomized
controlled studies. The population included males and females aged 2-32 undergoing an elective
tonsillectomy with or without an adenoidectomy. Two of the studies used varying doses of
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celecoxib, while one study used parecoxib as their Cox-2 inhibitors. Li X8 used intravenous
parecoxib sodium 1 mg/kg. Murto et al.9 used celecoxib 6 mg/kg preoperatively, followed by 3
mg/kg twice a day for five doses. Van Daele et al.4 used 200 mg celecoxib with a loading dose
the night before the surgery then twice daily for ten days. Subjects in this study were also
instructed to supplement the study drug with hydrocodone/acetaminophen liquid as needed. The
population was compared to a blind placebo group in all three trials. The outcome measured in
the studies was the average post-operative pain using various methods.
All three articles were published in English. Murto9 was co-published in French. They
were all found in peer-reviewed journals using PubMed as the database. All studies were found
using keywords “tonsillectomy”, “Cox-2 inhibitor” and “pain” and were chosen based on
relevance to the clinical question and importance of outcome to patient (POEM). Inclusion
criteria consisted of any randomized, controlled, and double or single blind trial published after
2006 that used a Cox-2 inhibitor for post-tonsillectomy pain. Studies were excluded from the
analysis if they did not use a Cox-2 inhibitor for pain control post operatively. All of the studies
used P-value as the statistic to evaluate the outcomes, where the P-value is statistically
significant if it is less than or equal to 0.05. See Table 1 below for the specific demographics
and characteristics of the studies included.
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Table 1: Demographics & Characteristics of included studies
Study

Type

# Pts

Li X 8

Double blind
placebocontrolled
randomized
clinical trial

60

Age
(yrs)
3-7

Murto9

Double Blind
randomized
Controlled study

282

2-18

Van
Daele 4

Randomized
Double Blind
Placebo
Controlled Trial

17

18+

Inclusion
Criteria
Children
aged 3-7
years, and
scheduled for
elective
tonsillectomy
, with or
without
adenoidecto
my under
general
anesthesia.
Children
(age 2-18
yr.)
scheduled for
elective
surgery were
enrolled over
a three-year
period
(2009-2012).

Minimum
age of 18
years and
medical
indication for
tonsillectomy

Exclusion Criteria
Allergy to the
Medications, serious
CV disease, liver or
kidney
dysfunction,
coagulation
disorders, asthma, or
an upper
respiratory infection.

-Extremes BMI,
abnormal blood
work, moderate to
severe OSA, any CI
to NSAIDs, allergy
to sulfa, risk of
pregnancy, recently
received
CYP2C9 inhibitors
or inducers,
language barrier,
and parent/
participant cognitive
impairment.
Hx of bleeding
disorder, liver
/kidney, CV disease,
allergy/reaction to
sulfa, NSAIDs, Cox2, pregnant,
abnormal lab values,
anyone currently
taking celecoxib,
anyone on warfarin
therapy,
uncontrolled HTN.

W/
D
0

Interventions

87

Study
participants
received either
placebo or an
adult dose
equivalent of
celecoxib (6 mg_
kg-1 )
preoperatively,
followed by 3
mg_ kg-1 twice
daily for five
doses
postoperatively
Were randomized
to 200 mg
celecoxib versus
placebo with a
loading dose the
night before
surgery
then twice daily
for 10 days

0

Received IV
Parecoxib
sodium 1 mg_
kg-1 or the same
volume of saline
just after
induction of
general
anesthesia.

Outcomes measured
The outcome measured in all three studies was post-operative pain. In Li X8 the outcome
was measured using the Children’s Hospital of Eastern Ontario Pain Scale (CHEOPS). The
CHEOPS is a behavior scale used to monitor pain and discomfort in children after surgery. In
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Murto9 the mean “worst 24-hr pain” (WP24HR) scores were recorded on post-operative day
(POD) 0-2 on a visual analogue scale (VAS) that was modified to reflect pain in the last 24 hours
instead of seven days. Zero was associated with a figure and wording and indicated no pain,
while 100 was similarly displayed and indicated severe pain. Children over five years old self
reported their scores, while participants younger than five were evaluated with a postoperative
parental pain measure modified to reflect the WP24HR by assessed twelve different behaviors to
a checklist. Scores were deemed clinically significant if it was greater than or equal to 10 mm on
a VAS or a 10-20% reduction in pain. Lastly, in Van Daele et al4 the outcome was evaluated
using participant recoded diaries with average daily pain, maximal daily pain, and pain after
eating.
Results
In the Li X 8 randomized control trial, 60 children aged 3-7 receiving elective
tonsillectomies were studied. As shown in table 1, patients were excluded if they have asthma,
an upper respiratory infection, and coagulation disorder, among others. This was to ensure
patient safety with anesthesia throughout the procedure and recovery period. They were
randomly split into two equal groups (group P and group S), each similar with respect to age,
weight, gender, surgical indication, and duration of surgery. Patients received either intravenous
parecoxib sodium 1mg/kg (Group P) or the same volume of saline (Group S) just after induction
of general anesthesia. After surgery the patients were taken to the PACU where they were
assessed every five minutes for the first fifteen minutes and every fifteen minutes thereafter.
Upon arrival to the surgical ward the patients were evaluated, they were also evaluated at 4, 8,
12, 16, 20, 24 hours, with pain being estimated with the CHEOPS. The highest pain scores were
recorded and used in the final analysis. If the patients CHEOPS score was less than or equal to
8, they received morphine 25 ug/kg as a rescue medication. As shown in table 2, the CHEOPS
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scores in the PACU of the patients in Group P were significantly lower than Group S (7 [5-8] vs.
9 [8-11] respectively. P=0.001). However, in the ward, the CHEOPS scores were similar
between the two groups. Also, patients in Group P received a statistically significantly lower
number of doses and amount of the rescue morphine for their pain (P=0.024). Overall, 57% of
participants in the parecoxib group, vs. 83% of participants in the saline group used rescue
morphine. Therefore, the NNT is 4 (table 3), indicating that for every 4 patients treated with
parecoxib instead of saline, one fewer patient will experience a reduction in pain compared to
those treated with saline.
Table 2: The number of children receiving rescue morphine, and CHEOPS scores in patients
who received parecoxib sodium (group P) or saline (group S)
Group P (n=30)
Group S (n=30)
Relative risk
P-Value
95% CI
PACU CHEOPS 7 (5-8.3)
9 (7.8-11)
0.001
Ward CHEOPS
4 (4-7)
5 (5-7.3)
0.29
# of children who 17/30 (57%)
25/30 (83%)
1.5 (1-2.1)
0.024
received rescue
morphine
Table 3: NNT of 4, indicating for every 4 patients who received parecoxib instead of saline, one
fewer patient will experience a reduction of pain
CER
EER
Absolute risk reduction (ARR)
Numbers needed to
treat (NNT) 1/ARR
83%
57%
.26
4
In Murto et al.9 there was initially 282 children enrolled, of that 195 were included in the
outcome analysis (celecoxib=101 and placebo=94). Of the 141 participants initially allocated to
the celecoxib group, 31 were lost to follow up or discontinued the intervention and of the 141 in
the placebo group, 38 participants were lost. The patients were randomized and the celecoxib
group received 6 mg/kg preoperatively, followed by 3 mg/kg twice a day for five doses. The
control group received OraBlend and a calcium carbonate excipient, which was identical in
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appearance and taste of the drug being studied. WP24HR scores were reported on POD 0-2.
There was a 95% drug compliance rate with those participants who returned their diaries. The
study used parent reports of pain instead of child using an intra-class correlation coefficient (ICC
with 95% CI: 0.75-0.82). The ICC is to measure the reliability of the measurement used. The
data showed the celecoxib group resulted in an 11% reduction in WP24HR score averaged over
POD 0-2 (95% CI: 0.3-14. P=0.04). The breakdown of POD 0-2 individually is shown in table
3. Furthermore, once the celecoxib was discontinued on POD 3, there was a 14% increase in
WP24HR compared to the placebo group. Additional, acetaminophen and morphine
consumption on POD 0-2 was lower in the celecoxib group (P=0.03 and P=0.06 respectively).
Since the p-value is greater than 0.05 the data is not statistically significant. Overall, the
incidence of adverse events between both groups was not significant, as was patient fatigue and
parent satisfaction.
Table 3: Parent report of post-adenotonsillectomy pain score on 100-mm VAS on POD 0-2.
WP24HR (95%CI))
Celecoxib
Placebo
P-value
POD 0

50 (44-57)

62 (56-69)

0.01

POD 1

64 (59-70)

75 (69-80)

<0.01

POD 2

63 (58-68)

64 (59-70)

0.70

Van Daele et al.4 was the only study of the three that used adults 18 or older. There were
17 patients selected for the study and 15 analyzed for the data (celecoxib=9 and Placebo=6).
Two patients were lost due to discontinued intervention from the placebo group. Patients were
excluded from this study if they had uncontrolled hypertension, were pregnant or could be
pregnant, on warfarin therapy, among others. These exclusion criteria differed from the other
studies due to the average age of the population being studied. This study also used two different
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methods for the tonsillectomy, the bipolar cautery (9 subjects) and the monopolar cautery (8
subjects). Both methods were evenly spilt between the two groups. Each subject in the study
provided had a self-reported journal with average daily pain, maximal daily pain, and pain after
eating on a scale of 0-10. As well as any addition medication (acetaminophen or morphine) used
for pain. The pain score were generally lower, but not statistically significant in the celecoxib
group as compared to the placebo. There was a significantly lower amount of morphine and
acetaminophen used in the celecoxib group (P=0.032). The average pain on day 0 was also
slightly lower in the celecoxib group with a P value of 0.442.
Table 4: Maximum pain and total addition morphine use of celecoxib vs. placebo on POD 0-7.
(Modified from the study, which showed data for POD 1-10)
Celecoxib n=9
Placebo n=6
95% CI
Day
Mean
Mean
Lower
Upper
P Value
Limit
Limit
Day 1
5.0
6.0
-3.5
1.5
.918
Day
5.1
6.0
-3.2
1.4
.918
Max Pain
2-4
Day
4.4
5.9
-2.7
1.9
.435
5-7
Treatment x day interaction P=0.67
Celecoxib n=9
Placebo n=6
95% CI
Day
Mean
Mean
Lower
Upper
P Value
Limit
Limit
Day 1
28.9
55.0
-72.9
20.7
.209
Day
30.4
72.4
-81.4
-2.6
.032
Total
2-4
Morphine
Day
27.8
69.7
-81.4
-2.5
.032
equivalent 5-7
Treatment x day interaction P=0.036

Discussion
The studies presented conflicting evidence, as two out of the three showed that a Cox-2
inhibitor could significantly help with pain post tonsillectomy with or without adenoidectomy.
Van Daele et al4 showed that celecoxib did not significantly decrease pain post tonsillectomy,
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however it did show a statistically significant increase in acetaminophen and morphine use in the
placebo group compared to the celecoxib group. Although overall pain scores were not
significant, the data suggests patients in the placebo group may have used more pain relieving
drugs in order to reach a common pain level with the celecoxib group. As shown in table 1, and
stated previous, Van Daele et al4 used a study population of 18+ that included adults, which
could have also contributed to the varying results. Both Li X8 and Murto9 showed that, although
minimal, there was a clinically significant decrease in pain scores from the Cox-2 group versus
the placebo.
Cox-2 inhibitors have been used to decrease pain and inflammation for many conditions,
such as rheumatoid arthritis, osteoarthritis, juvenile idiopathic arthritis ankylosing spondylitis
and primary dysmenorrhea3. There were two different Cox-2 inhibitors used in the studies. The
most common adverse effects of celecoxib are headache, nausea, diarrhea, abdominal pain and
insomnia10. NSAIDs have a black box warning for increasing the risk for myocardial infraction,
stroke, and serious stomach and intestine bleeding, ulceration or perforation. This drug should
only be used in pregnant women when the benefits outweigh the risks10. Parecoxib, used in Li
X8, is indicated for short-term treatment of postoperative pain in adults. The most common side
effect is nausea and should not be used in people who are allergic to any of the components, have
had a myocardial infarction, or stroke or liver disease11.
There were many limitations found in this review. In both Li X8 and Van Daele et al4 the
population size studied was very small with 60 people in Li X and just 17 in Van Daele. Li X8
also discussed a few limitations of their study. Using the CHEOPS for the assessment of pain in
children aged three to seven is controversial and does not correlate with the self-reported pain
measures in children8. They also talk about the use of remifentanil for the tonsillectomy, instead
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of fentanyl, which is associated with higher postoperative pain scores, as well as the use of
morphine at the end of surgery to reduce the need for postoperative rescue analgesics. Lastly,
this study talks about the limitations with the safety of the drug parecoxib and the need for
further study to discover the optimal dose to reduce postoperative pain. In Murto9 they discussed
limitations such as the refusal and dropout rate due to the length of the study and the use of an
unapproved drug to manage pain in children. It also discussed the use of WP24HR to report pain
as a subjective measurement that relied on the recall of the patients or the parents. However, the
single assessment for pain was clinically significant and was less likely to miss severe pain
associated with recent analgesic use or by using predetermined intervals as a measurement9. In
all three studies another limitation was that pain could not accurately be determined due to the
morphine and/or acetaminophen used in conjunction. Also, the amount of the drug used and at
what times varied from study to study.
Conclusion
The evidence put forth in the three studies shows conflicting results, which warrants
further research regarding the use of Cox-2 inhibitors for post-tonsillectomy pain. Li X8 and
Murto et al9 both concluded that the use of a Cox-2 inhibitors does reduce pain posttonsillectomy. Van Daele et al4 concluded there was no statistically significant decrease in pain,
but there was a statistically significant increase in postoperative narcotic and acetaminophen use
in the placebo group for pain. Due to the difference in population and size of Van Daele et al4, it
can be said that Cox-2 inhibitors does decrease pain post-tonsillectomy with or without
adenoidectomy in children aged two to eighteen, but further testing is necessary for the adult
population. These studies looked at pain and co-analgesic consumption in the early stages of
recovery, therefore, more research should be done to observe sustained pain relief and optimal
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medication dose. These studies should consider using the intervention for a longer period of
time with a standard dose throughout to ensure validity of the study. The average patient
undergoing a tonsillectomy is in the pediatric population, consequently it is difficult to further
study the adult population due to low number of tonsillectomies in the population.
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